227 related articles for article (PubMed ID: 31852717)
1. Intratumoral Plasmid IL12 Electroporation Therapy in Patients with Advanced Melanoma Induces Systemic and Intratumoral T-cell Responses.
Greaney SK; Algazi AP; Tsai KK; Takamura KT; Chen L; Twitty CG; Zhang L; Paciorek A; Pierce RH; Le MH; Daud AI; Fong L
Cancer Immunol Res; 2020 Feb; 8(2):246-254. PubMed ID: 31852717
[TBL] [Abstract][Full Text] [Related]
2. Intratumoral Delivery of Plasmid IL12 Via Electroporation Leads to Regression of Injected and Noninjected Tumors in Merkel Cell Carcinoma.
Bhatia S; Longino NV; Miller NJ; Kulikauskas R; Iyer JG; Ibrani D; Blom A; Byrd DR; Parvathaneni U; Twitty CG; Campbell JS; Le MH; Gargosky S; Pierce RH; Heller R; Daud AI; Nghiem P
Clin Cancer Res; 2020 Feb; 26(3):598-607. PubMed ID: 31582519
[TBL] [Abstract][Full Text] [Related]
3. Melanoma treatment with intratumoral electroporation of tavokinogene telseplasmid (pIL-12, tavokinogene telseplasmid).
Canton DA; Shirley S; Wright J; Connolly R; Burkart C; Mukhopadhyay A; Twitty C; Qattan KE; Campbell JS; Le MH; Pierce RH; Gargosky S; Daud A; Algazi A
Immunotherapy; 2017 Dec; 9(16):1309-1321. PubMed ID: 29064334
[TBL] [Abstract][Full Text] [Related]
4. Intratumoral Plasmid IL12 Expands CD8
Telli ML; Nagata H; Wapnir I; Acharya CR; Zablotsky K; Fox BA; Bifulco CB; Jensen SM; Ballesteros-Merino C; Le MH; Pierce RH; Browning E; Hermiz R; Svenson L; Bannavong D; Jaffe K; Sell J; Foerter KM; Canton DA; Twitty CG; Osada T; Lyerly HK; Crosby EJ
Clin Cancer Res; 2021 May; 27(9):2481-2493. PubMed ID: 33593880
[TBL] [Abstract][Full Text] [Related]
5. Intratumoral delivery of tavokinogene telseplasmid yields systemic immune responses in metastatic melanoma patients.
Algazi A; Bhatia S; Agarwala S; Molina M; Lewis K; Faries M; Fong L; Levine LP; Franco M; Oglesby A; Ballesteros-Merino C; Bifulco CB; Fox BA; Bannavong D; Talia R; Browning E; Le MH; Pierce RH; Gargosky S; Tsai KK; Twitty C; Daud AI
Ann Oncol; 2020 Apr; 31(4):532-540. PubMed ID: 32147213
[TBL] [Abstract][Full Text] [Related]
6. Intratumoral Electroporation of Plasmid Encoded IL12 and Membrane-Anchored Anti-CD3 Increases Systemic Tumor Immunity.
Han M; Nguyen B; Lee JY; Browning E; Zhang J; Mukhopadhyay A; Gujar R; Salazar J; Hermiz R; Svenson L; Rolig AS; Redmond WL; Algazi AP; Daud AI; Canton DA; Twitty CG
Mol Cancer Res; 2022 Jun; 20(6):983-995. PubMed ID: 35302641
[TBL] [Abstract][Full Text] [Related]
7. Electrochemo-gene therapy of cancer: intratumoral delivery of interleukin-12 gene and bleomycin synergistically induced therapeutic immunity and suppressed subcutaneous and metastatic melanomas in mice.
Kishida T; Asada H; Itokawa Y; Yasutomi K; Shin-Ya M; Gojo S; Cui FD; Ueda Y; Yamagishi H; Imanishi J; Mazda O
Mol Ther; 2003 Nov; 8(5):738-45. PubMed ID: 14599806
[TBL] [Abstract][Full Text] [Related]
8. Vaccination with mRNA-electroporated dendritic cells induces robust tumor antigen-specific CD4+ and CD8+ T cells responses in stage III and IV melanoma patients.
Aarntzen EH; Schreibelt G; Bol K; Lesterhuis WJ; Croockewit AJ; de Wilt JH; van Rossum MM; Blokx WA; Jacobs JF; Duiveman-de Boer T; Schuurhuis DH; Mus R; Thielemans K; de Vries IJ; Figdor CG; Punt CJ; Adema GJ
Clin Cancer Res; 2012 Oct; 18(19):5460-70. PubMed ID: 22896657
[TBL] [Abstract][Full Text] [Related]
9. Talimogene laherparepvec upregulates immune-cell populations in non-injected lesions: findings from a phase II, multicenter, open-label study in patients with stage IIIB-IVM1c melanoma.
Malvehy J; Samoylenko I; Schadendorf D; Gutzmer R; Grob JJ; Sacco JJ; Gorski KS; Anderson A; Pickett CA; Liu K; Gogas H
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33785610
[TBL] [Abstract][Full Text] [Related]
10. Intratumoral IL12 mRNA Therapy Promotes TH1 Transformation of the Tumor Microenvironment.
Hewitt SL; Bailey D; Zielinski J; Apte A; Musenge F; Karp R; Burke S; Garcon F; Mishra A; Gurumurthy S; Watkins A; Arnold K; Moynihan J; Clancy-Thompson E; Mulgrew K; Adjei G; Deschler K; Potz D; Moody G; Leinster DA; Novick S; Sulikowski M; Bagnall C; Martin P; Lapointe JM; Si H; Morehouse C; Sedic M; Wilkinson RW; Herbst R; Frederick JP; Luheshi N
Clin Cancer Res; 2020 Dec; 26(23):6284-6298. PubMed ID: 32817076
[TBL] [Abstract][Full Text] [Related]
11. Autologous melanoma vaccine induces antitumor and self-reactive immune responses that affect patient survival and depend on MHC class II expression on vaccine cells.
Lotem M; Machlenkin A; Hamburger T; Nissan A; Kadouri L; Frankenburg S; Gimmon Z; Elias O; David IB; Kuznetz A; Shiloni E; Peretz T
Clin Cancer Res; 2009 Aug; 15(15):4968-77. PubMed ID: 19602547
[TBL] [Abstract][Full Text] [Related]
12. Identification of known and novel immunogenic T-cell epitopes from tumor antigens recognized by peripheral blood T cells from patients responding to IL-2-based treatment.
Scheibenbogen C; Sun Y; Keilholz U; Song M; Stevanovic S; Asemissen AM; Nagorsen D; Thiel E; Rammensee HG; Schadendorf D
Int J Cancer; 2002 Mar; 98(3):409-14. PubMed ID: 11920592
[TBL] [Abstract][Full Text] [Related]
13. T-Cell Therapy Enabling Adenoviruses Coding for IL2 and TNFα Induce Systemic Immunomodulation in Mice With Spontaneous Melanoma.
Tähtinen S; Blattner C; Vähä-Koskela M; Saha D; Siurala M; Parviainen S; Utikal J; Kanerva A; Umansky V; Hemminki A
J Immunother; 2016; 39(9):343-354. PubMed ID: 27741089
[TBL] [Abstract][Full Text] [Related]
14. Induction of antigen-specific CD8+ cytotoxic T cells by dendritic cells co-electroporated with a dsRNA analogue and tumor antigen mRNA.
Michiels A; Breckpot K; Corthals J; Tuyaerts S; Bonehill A; Heirman C; Thielemans K; Aerts JL
Gene Ther; 2006 Jul; 13(13):1027-36. PubMed ID: 16511519
[TBL] [Abstract][Full Text] [Related]
15. Intratumoral interferon-gamma increases chemokine production but fails to increase T cell infiltration of human melanoma metastases.
Mauldin IS; Wages NA; Stowman AM; Wang E; Smolkin ME; Olson WC; Deacon DH; Smith KT; Galeassi NV; Chianese-Bullock KA; Dengel LT; Marincola FM; Petroni GR; Mullins DW; Slingluff CL
Cancer Immunol Immunother; 2016 Oct; 65(10):1189-99. PubMed ID: 27522581
[TBL] [Abstract][Full Text] [Related]
16. Induction of strong and persistent MelanA/MART-1-specific immune responses by adjuvant dendritic cell-based vaccination of stage II melanoma patients.
Tuettenberg A; Becker C; Huter E; Knop J; Enk AH; Jonuleit H
Int J Cancer; 2006 May; 118(10):2617-27. PubMed ID: 16353138
[TBL] [Abstract][Full Text] [Related]
17. Induction of circulating tumor-reactive CD8+ T cells after vaccination of melanoma patients with the gp100 209-2M peptide.
Meijer SL; Dols A; Jensen SM; Hu HM; Miller W; Walker E; Romero P; Fox BA; Urba WJ
J Immunother; 2007; 30(5):533-43. PubMed ID: 17589294
[TBL] [Abstract][Full Text] [Related]
18. Polyfunctional response by ImmTAC (IMCgp100) redirected CD8
Boudousquie C; Bossi G; Hurst JM; Rygiel KA; Jakobsen BK; Hassan NJ
Immunology; 2017 Nov; 152(3):425-438. PubMed ID: 28640942
[TBL] [Abstract][Full Text] [Related]
19. Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity.
Palucka AK; Ueno H; Connolly J; Kerneis-Norvell F; Blanck JP; Johnston DA; Fay J; Banchereau J
J Immunother; 2006; 29(5):545-57. PubMed ID: 16971810
[TBL] [Abstract][Full Text] [Related]
20. Intralymphatic dendritic cell vaccination induces tumor antigen-specific, skin-homing T lymphocytes.
Grover A; Kim GJ; Lizée G; Tschoi M; Wang G; Wunderlich JR; Rosenberg SA; Hwang ST; Hwu P
Clin Cancer Res; 2006 Oct; 12(19):5801-8. PubMed ID: 17020987
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
